Factors associated with high-risk human papillomavirus infection and high-grade cervical neoplasia: A population-based study in Paraguay.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
02
11
2018
accepted:
23
05
2019
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
12
2
2020
Statut:
epublish
Résumé
Cervical cancer (CC) is one of the leading causes of cancer mortality among women from Paraguay, with high incidence and mortality rates (31.2 and 16 per 100 000 women, respectively). Although the risk factors associated with high-risk human papillomavirus (hrHPV) infection and preneoplastic cervical lesions are widely studied, population-based characteristics of particular settings may influence the feasibility of HPV-based CC screening implementation. This study aimed to explore factors associated with hrHPV infection and high-grade cervical neoplasia in hrHPV-positive (hrHPV+) women from Paraguay. A total of 5677 women aged 30-64 years from the Central Department of Paraguay were screened with HPV test (Hybrid Capture 2) and Pap smear. Sociodemographic and risk factor interviews were conducted. hrHPV+ women were referred to colposcopy and women with an abnormal colposcopy had a biopsy taken. The outcomes recorded were the hrHPV status and the presence of high-grade cervical intraepithelial neoplasia or worse (CIN2+) among hrHPV+ women. Associations were investigated using multivariate logistic regressions. hrHPV prevalence was 13.8% (95%CI 13.0-14.8). This value decreased with the age of women (p-trend<0.001) and increased with the lifetime number of sexual partners (p-trend<0.001) and number of previous female partners of their current male partner if women had had one lifetime sexual partner (p-trend<0.001), increasing from 3.06 (95%CI 0.073-20.9) if partners had had one previous female partner to 9.19 (95%CI 2.36-61.1) if they had had eight or more. In hrHPV+ women, CIN2+ prevalence was 10.7% (95%CI 8.58-13.2) and increased with time since the last Pap smear (p-trend<0.001) and with the increasing number of pregnancies (p-trend = 0.05). In these settings, the sexual behavior of women and their male partners is associated with hrHPV infection. In hrHPV+ women, underscreening practices and multiple pregnancies are associated with CIN2+. This knowledge can contribute to public health policies for CC prevention and control in Paraguay.
Sections du résumé
BACKGROUND
Cervical cancer (CC) is one of the leading causes of cancer mortality among women from Paraguay, with high incidence and mortality rates (31.2 and 16 per 100 000 women, respectively). Although the risk factors associated with high-risk human papillomavirus (hrHPV) infection and preneoplastic cervical lesions are widely studied, population-based characteristics of particular settings may influence the feasibility of HPV-based CC screening implementation. This study aimed to explore factors associated with hrHPV infection and high-grade cervical neoplasia in hrHPV-positive (hrHPV+) women from Paraguay.
METHODS
A total of 5677 women aged 30-64 years from the Central Department of Paraguay were screened with HPV test (Hybrid Capture 2) and Pap smear. Sociodemographic and risk factor interviews were conducted. hrHPV+ women were referred to colposcopy and women with an abnormal colposcopy had a biopsy taken. The outcomes recorded were the hrHPV status and the presence of high-grade cervical intraepithelial neoplasia or worse (CIN2+) among hrHPV+ women. Associations were investigated using multivariate logistic regressions.
RESULTS
hrHPV prevalence was 13.8% (95%CI 13.0-14.8). This value decreased with the age of women (p-trend<0.001) and increased with the lifetime number of sexual partners (p-trend<0.001) and number of previous female partners of their current male partner if women had had one lifetime sexual partner (p-trend<0.001), increasing from 3.06 (95%CI 0.073-20.9) if partners had had one previous female partner to 9.19 (95%CI 2.36-61.1) if they had had eight or more. In hrHPV+ women, CIN2+ prevalence was 10.7% (95%CI 8.58-13.2) and increased with time since the last Pap smear (p-trend<0.001) and with the increasing number of pregnancies (p-trend = 0.05).
CONCLUSION
In these settings, the sexual behavior of women and their male partners is associated with hrHPV infection. In hrHPV+ women, underscreening practices and multiple pregnancies are associated with CIN2+. This knowledge can contribute to public health policies for CC prevention and control in Paraguay.
Identifiants
pubmed: 31246959
doi: 10.1371/journal.pone.0218016
pii: PONE-D-18-31694
pmc: PMC6597051
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0218016Subventions
Organisme : NCI NIH HHS
ID : UH3 CA202730
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2002 Mar 30;359(9312):1093-101
pubmed: 11943256
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):326-33
pubmed: 16492924
Salud Publica Mex. 2010 Nov-Dec;52(6):544-59
pubmed: 21271014
Vaccine. 2012 Nov 20;30 Suppl 5:F117-22
pubmed: 23199954
Int J Cancer. 2001 Feb 1;91(3):412-20
pubmed: 11169968
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Br J Cancer. 2001 May 4;84(9):1219-26
pubmed: 11336474
Vaccine. 2008 Aug 19;26 Suppl 11:L16-36
pubmed: 18945400
J Infect Dis. 2010 Dec 15;202(12):1789-99
pubmed: 21067372
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99
pubmed: 23199969
Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2148-53
pubmed: 17119039
Cancer Causes Control. 2016 Dec;27(12):1437-1446
pubmed: 27822586
J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88
pubmed: 20841605
Lancet. 2007 Nov 10;370(9599):1609-21
pubmed: 17993361
Int J Gynecol Cancer. 2011 Dec;21(9):1654-63
pubmed: 21892094
Papillomavirus Res. 2016 Dec;2:89-96
pubmed: 29074191
BMC Infect Dis. 2012 Jun 26;12:145
pubmed: 22734435
J Infect Dis. 2005 Jun 1;191(11):1796-807
pubmed: 15871111
Vaccine. 2008 Aug 19;26 Suppl 11:L96-L107
pubmed: 18945407
Lancet Infect Dis. 2007 Jul;7(7):453-9
pubmed: 17597569
N Engl J Med. 2009 Apr 2;360(14):1385-94
pubmed: 19339719
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2271-6
pubmed: 15598792
J Natl Cancer Inst Monogr. 2003;(31):20-8
pubmed: 12807941
PLoS One. 2016 Jan 25;11(1):e0147029
pubmed: 26808155
J Med Virol. 2011 Aug;83(8):1351-7
pubmed: 21618554
Br J Cancer. 2009 Sep 1;101(5):865-70
pubmed: 19654578
Cancer Causes Control. 2010 Oct;21(10):1693-700
pubmed: 20617376
J Natl Cancer Inst. 2000 Mar 15;92(6):464-74
pubmed: 10716964
Vaccine. 2008 Aug 19;26 Suppl 11:L37-48
pubmed: 18945401
Int J Cancer. 2013 Sep 15;133(6):1271-85
pubmed: 22961444
BMC Infect Dis. 2013 Nov 09;13:531
pubmed: 24206645
Br J Cancer. 2002 Jul 29;87(3):324-33
pubmed: 12177803
Int J Cancer. 2000 Feb 15;85(4):486-91
pubmed: 10699919
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Med Virol. 2012 Oct;84(10):1628-35
pubmed: 22930512
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
PLoS One. 2017 Jan 23;12(1):e0170189
pubmed: 28114325